相关实验视频

Updated: Jan 16, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

对于血栓栓塞性疾病的纤维解析疗法:已批准的指示和未来的方向

Sina Rashedi¹, Hannah Leyva¹, Nada Hamade¹

¹Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Journal of the American College of Cardiology

|October 1, 2025

概括

纤维溶解疗法使用诸如高高等药物来溶解血栓,帮助血管再通道化,但增加出血风险. 本综述详细介绍了纤维素分解在各种血栓栓塞性疾病中的当前和未来用途.

科学领域:

心血管医学心血管医学
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

纤维溶解药物治疗对于通过降解纤维素凝块来管理血栓栓塞性疾病至关重要.
关键的纤维溶解剂包括链酶,尿酶和复合组织血清原激素激活剂 (tPA) 衍生物,如阿尔特酶,基酶和网酶.
虽然有效,但纤维素溶解会增加出血并发症的风险,包括内出血.

研究的目的:

在血栓栓塞性疾病管理中提供纤维溶解剂的全面概述.
讨论当前的应用,已批准的指示,以及纤维素分解的演变作用.
为了探索纤维解药疗法的未来方向.

主要方法:

关于纤维溶解剂及其应用的文献综述.
分析目前在各种血栓栓塞性疾病中的临床用途.
检查历史发展和未来研究趋势.

主要成果:

纤维解药疗法是急性缺血性中风和血液动力学损害性肺栓塞 (PE) 的支柱.
用导管导向纤维解析正在研究中等风险PE,深静脉血栓和四肢缺血.
纤维溶解剂用于各种疾病,如器械血栓症和视网膜动脉封闭.

结论:

纤维溶解药物治疗对于血栓栓塞性疾病至关重要,应用范围正在扩大.
目前正在进行的研究重点是优化安全性和有效性,特别是在改性tPA衍生物中.
未来的方向包括改进导管定向技术和探索纤维素分解的新指标.

关键词:

纤维溶解剂是一种纤维溶解剂.血栓塞栓症血栓塞栓症血栓塞栓症血栓溶解药物治疗的方法血栓形成的原因是血栓形成.

更多相关视频

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

相关概念视频

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Pulmonary Embolism III: Nursing Management

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...